Myriad Genetics (MYGN) said late Tuesday that it seeks to reach a resolution with UnitedHealth Group's (UNH) UnitedHealthcare on medical policy for pharmacogenetic tests, including Myriad's GeneSight test, before the yearend, but discussions may continue into early next year.

"We remain steadfast in our confidence in the clinical validity and utility of GeneSight, which we believe is supported by clinical evidence, including peer-reviewed research studies," Myriad quoted its chief executive officer, Paul Diaz, as saying in a statement.

Last month, UnitedHealthcare published its updated medical policy limiting coverage access to multi-gene panel pharmacogenetic tests, including the GeneSight test, under the commercial and individual exchange benefit plans beginning Jan. 1.